Acquisitions, Dispositions, and Funded Research and Development Arrangements (Tables)

12 Months Ended

Apr. 24, 2026

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

Schedule of Business Combination, Recognized Asset Acquired and Liability Assumed

The following tables summarize the preliminary fair value of consideration transferred and the preliminary fair values of the assets acquired and liabilities assumed:


(in millions)
Cash consideration paid at closing	$	410
Fair value of contingent consideration	115
Total consideration transferred	525
Fair value of previously held equity interest in CathWorks	93
Settlement of debt and accrued interest due from CathWorks	88
Settlement of pre-existing relationships	12
Total purchase price	$	718


(in millions)
Current assets	$	17
Property, plant, and equipment, net	11
Goodwill	555
Other intangible assets	200
Other assets	1
Total assets acquired	$	784

Current liabilities	$	7
Accrued income taxes	38
Total current liabilities	45
Deferred tax liabilities	21
Other noncurrent liabilities	1
Total liabilities assumed	$	66

Net assets acquired	$	718

Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions

The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:


	Fiscal Year
(in millions)	2026		2025
Beginning balance	$	81	$	149
Purchase price contingent consideration	115		20

Payments	(28)		(86)
Change in fair value	(5)		(2)

Ending balance	$	163	$	81

The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:


	Fiscal Year
(in millions)	2026		2025
Beginning balance	$	13	$	58

Change in fair value	(13)		(45)
Ending balance	$	—	$	13

Schedule of Significant Unobservable Inputs

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:


(in millions)	Fair Value at April 24, 2026		Unobservable Input	Range	Weighted Average (1)
Revenue and other performance-based payments	$	141	Discount rate	15.0% - 28.2%	16.6%
			Projected fiscal year of payment	2027 - 2029	2027
Product development and other milestone-based payments	$	22	Discount rate	5.5%	5.5%
			Projected fiscal year of payment	2027 - 2028	2027

(1)Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.